|
 The company's oral enzyme ribaxamase met the main goal of
significantly reducing Clostridium difficile infection (CDI) versus
a placebo in the 412-patient study.
Prolonged use of antibiotics can allow this common intestinal
inhabitant to explode into a lethal infection as antibiotics kill
off its beneficial rivals in the gut.
Spread through hospital surfaces and human contact, C. difficile
most often affects the elderly. It causes severe diarrhea, can
damage the colon and is difficult to treat.
The company's shares were up 24 percent at $1.10 in premarket
trading.
(Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
